Ann: MDR Jun-17 Quarterly Report & 4C, page-2

  1. 587 Posts.
    lightbulb Created with Sketch. 23
    •Q4 operating cash inflow was $1.4m up 481% on same quarter prior year

    • Revenue of $1.43 million, an increase of 12% on the March 2017 quarter ($1.27m) and 367% ahead of the June 2016 quarter

    • FY17 total operating cash inflow was $5.02m ($5.5m including R&D Rebate) and FY17 Operating revenue totalled $4.24m (excludes R&D Rebate), 210% higher than FY16

    • Positive operational performance and growth across key metrics: o Over 830,000 users on the MedAdvisor platform, an increase of 17% on the March 2017 quarter o Expanded the MedAdvisor Pharmacy Network, to over 2,600+, with MedAdvisor now providing its platform to all of Discount Drug Stores (DDS) nationwide

    • Dr David Chatterton (ex Aconex Ltd CTO – ASX:ACX) appointed Chief Technology Officer ahead of next phase of growth • New pharmacy software platform developed “PlusOne” that will provide additional pharmacy services and expand revenue opportunities for MedAdvisor and network pharmacy customers
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
7.9¢
Change
-0.001(1.25%)
Mkt cap ! $49.35M
Open High Low Value Volume
7.7¢ 8.0¢ 7.7¢ $53.73K 682.6K

Buyers (Bids)

No. Vol. Price($)
1 65644 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 35512 2
View Market Depth
Last trade - 14.22pm 24/06/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.